Clinical Trials
5 trialsNCT04744831 2026-01-14
DESTINY-CRC02
Daiichi Sankyo
Phase 2 Completed
NCT04989816 2024-11-21
DG-06
AstraZeneca
Phase 2 Completed
NCT03368196 2022-11-03
DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein
Daiichi Sankyo
Phase 1 Completed
NCT03329690 2022-03-18
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]
Daiichi Sankyo
Phase 2 Completed
NCT03384940 2021-10-18
DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)
Daiichi Sankyo
Phase 2 Completed